سعر ازجوكلاتينس محلول معقم للعين 5 مل 2022

Brimonidine tartrate + timolol ophthalmic solution, 5 ml bottle; intraocular pressure-lowering eye drops (Grand Pharma for APIC, Egypt).

• Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOPPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Reduction of IOP in chronic open-angle glaucoma or ocular hypertension insufficiently responsive to topical beta-blockersPopulation: Adultselectronic medicines compendium (eMC)

• Most common adverse reactions (about 5-15%): allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning and stinging.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Most commonly reported adverse reactions: conjunctival hyperaemia (about 15%) and burning sensation in the eye (about 11%); most were mild and led to discontinuation in only a small proportion of patients.International label, same formulation · electronic medicines compendium (eMC)

• Reactive airway disease including bronchial asthma or history of asthma, severe COPD; sinus bradycardia, second- or third-degree AV block, overt cardiac failure, cardiogenic shock; neonates and infants under 2 years; hypersensitivity to any component.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Additionally (UK SmPC): sick sinus syndrome, sino-atrial block; patients on monoamine oxidase inhibitor therapy; patients on antidepressants affecting noradrenergic transmission (e.g. tricyclic antidepressants, mianserin).International label, same formulation · electronic medicines compendium (eMC)

• Timolol is absorbed systemically: the same adverse reactions as with systemic beta-blockers may occur, including severe respiratory reactions and cardiac reactions (death from bronchospasm in asthmatics and from cardiac failure has been reported). Use caution in cardiac failure, COPD/bronchospastic disease, cerebral or coronary insufficiency and Raynaud phenomenon.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Beta-blockers may mask signs of hypoglycemia (use caution in diabetes, especially insulin-treated or labile diabetes) and of hyperthyroidism (abrupt withdrawal may precipitate thyroid storm); may potentiate muscle weakness in myasthenia gravis; patients with a history of severe anaphylaxis may be unresponsive to usual epinephrine doses; consider gradual withdrawal before major surgery.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Ocular hypersensitivity reactions have been reported with brimonidine; bacterial keratitis has been associated with contaminated multiple-dose containers.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Antihypertensives and cardiac glycosidesBrimonidine may reduce blood pressure; use caution with antihypertensives and/or cardiac glycosides.DailyMed (U.S. National Library of Medicine)
• Oral or intravenous beta-blockersPotential additive effects on systemic beta-blockade and intraocular pressure; concomitant use of two topical beta-blockers is not recommended.DailyMed (U.S. National Library of Medicine)
• Oral calcium antagonists, catecholamine-depleting drugs (e.g. reserpine), digitalisPossible additive effects: AV conduction disturbances, left ventricular failure, hypotension or marked bradycardia.DailyMed (U.S. National Library of Medicine)

• Available data on use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes; animal studies did not show teratogenicity at clinically relevant exposures.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Should not be used during pregnancy unless clearly necessary. If used until delivery, the neonate should be carefully monitored during the first days of life for signs of beta-blockade (e.g. bradycardia, hypotension, respiratory distress, hypoglycaemia).International label, same formulation · electronic medicines compendium (eMC)
• Timolol is present in human milk; because of the potential for serious adverse reactions in breastfed infants (e.g. CNS depression and apnea from brimonidine), breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Brimonidine: Alpha-2 agonist that lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow (US Combigan label).
• Timolol: Non-selective beta1/beta2 blocker without significant intrinsic sympathomimetic or membrane-stabilizing activity; lowers intraocular pressure (US Combigan label).